Skip to Content
  • Previous Rank
    224
  • Revenues ($M)
    $15,281.0
  • Revenue Percent Change
    17.5%
  • Profits ($M)
    $4,046.0
  • Profits Percent Change
    37.6%
  • Assets ($M)
    $35,480.0
  • Employees
    8,852

The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multiple myeloma, inflammatory diseases, and various forms of cancer.

41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Info

CEO
Mark J. Alles
CEO Title
Chairman & Chief Executive Officer
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Summit, N.J.
Websitehttp://www.celgene.com
Years on Fortune 500 List8
Employees8,852

Celgene Rank History

placeholder

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$15,281.017.5%
Profits ($M)$4,046.037.6%
Assets ($M)$35,480.0-
Total Stockholder Equity ($M)$6,161.0-

Profit Ratios

Profit as % of Revenues26.5%
Profits as % of Assets11.4%
Profits as % of Stockholder Equity65.7%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)5.51
EPS % Change (from 2017)51.4%
EPS % Change (5 year annual rate)26.7%
EPS % Change (10 year annual rate)-

Total Return

Total Return to Investors (2018)-38.6%
Total Return to Investors (5 year, annualized)-5.4%
Total Return to Investors (10 year, annualized)8.8%